West Haven antiviral-drug developer NanoViricides Inc. says it won a U.S. patent on a key component of its bioscience that enables its treatment to mimic a virus' host cell so it can chemically attack and destroy the germ.
NanoViricides said the U.S. Patents and Trademarks Office is due to formally issue Tuesday patent No. 8,173,764 for "Solubilization and Targeted Delivery of Drugs with Self-Assembling Amphiphilic Polymers." Unless extended, the patent expires Oct. 1, 2026, the company said.
A number of African countries and New Zeand already have issued patents on the biotechnology, with several European nations expected to follow suit, the company said.
Several of NanoViricides co-founders are among the U.S. patent's named inventors: Anil R. Diwan, Jayant G. Tatake and Ann L. Onton.
The patents have been assigned to AllExcel Inc., where the groundbreaking research was performed. AllExcel, in turn, has contractually transferred the patent to TheraCour Pharma Inc., a West Haven company owned and headed by Diwan. Diwan is an AllExcel director.
NanoViricides is pursuing U.S. Food & Drug Administration review and approval of its FluCide antiviral, seen as a potential blockbuster.
NanoViricides also is developing treatments for some of the world's most prevalent and debilitating ailments traced to viruses, including bird and swine flu, herpes, HIV, ebola and dengue fever.